Zobrazeno 1 - 10
of 177
pro vyhledávání: '"Marinus A. Moerland"'
Autor:
Katelijne M. Van Vliet-van den Ende, Paulien G. Hoogendoorn-Mulder, Rogier I. Schokker, Marinus A. Moerland, Petra S. Kroon, Judith M. Roesink, Raquel Dávila Fajardo, Femke Van der Leij, Ina M. Jürgenliemk-Schulz
Publikováno v:
Technical Innovations & Patient Support in Radiation Oncology, Vol 31, Iss , Pp 100262- (2024)
Introduction: At our department we have a dedicated 1.5 Tesla MRI/HDR brachytherapy suite, which provides the possibility of repeated MRI scanning before, during and after applicator insertion and before and/or after irradiation for patients with adv
Externí odkaz:
https://doaj.org/article/cdd0c1bd959f4097a3fb0c579b353945
Autor:
Mischa de Ridder, Milena Smolic, Maarten Kastelijns, Samantha Kloosterman, Stefan van der Vegt, Johannes A. Rijken, Ina M. Jürgenliemk-Schulz, Homan Dehnad, Petra S. Kroon, Marinus A. Moerland
Publikováno v:
Physics and Imaging in Radiation Oncology, Vol 31, Iss , Pp 100629- (2024)
Background and purpose: Brachytherapy is treatment of choice for early stage nasal vestibule cancer. Over the years improvements were achieved by means of image guided target definition, interstitial implant techniques and also individual mold techni
Externí odkaz:
https://doaj.org/article/73c499b5f33e40be996bcf51d18c6b69
Autor:
Thomas Willigenburg, Marieke J. van Son, Sandrine M.G. van de Pol, Wietse S.C. Eppinga, Jan J.W. Lagendijk, Hans C.J. de Boer, Marinus A. Moerland, Jochem R.N. van der Voort van Zyp, Max Peters
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 30, Iss , Pp 7-14 (2021)
Background and purpose: Magnetic resonance-guided focal salvage high-dose-rate brachytherapy (FS-HDR-BT) for radiorecurrent prostate cancer (PCa) shows low toxicity rates. However, biochemical failure (BF) after treatment occurs frequently. We develo
Externí odkaz:
https://doaj.org/article/d6ee9d55c99244a3b1ac0df6173ee7d4
Autor:
Thomas Willigenburg, Ellis Beld, Jochem Hes, Jan J.W. Lagendijk, Hans C.J. de Boer, Marinus A. Moerland, Jochem R.N. van der Voort van Zyp
Publikováno v:
Physics and Imaging in Radiation Oncology, Vol 15, Iss , Pp 60-65 (2020)
Background and Purpose: Magnetic resonance imaging (MRI)-guided focal salvage high-dose-rate brachytherapy (FS-HDR-BT) is one of the treatment options for radiorecurrent localized prostate cancer. However, due to the invasive nature of the treatment,
Externí odkaz:
https://doaj.org/article/7d2c9236c92743dc8a24e466f5c4c393
Autor:
Max Peters, Marjanne A. Piena, Lotte M.G. Steuten, Jochem R.N. van der Voort van Zyp, Marinus A. Moerland, Marco van Vulpen
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 8, Iss 6, Pp 484-491 (2016)
Purpose: Focal salvage (FS) iodine 125 ( 125 I) brachytherapy could be an effective treatment for locally radiorecurrent prostate cancer (PCa). Toxicity is often reduced compared to total salvage (TS) while cancer control can be maintained, which cou
Externí odkaz:
https://doaj.org/article/d3cce4841fac432ebe34af092b44e1ee
Autor:
Sandrine M.G. van de Pol, Wietse S.C. Eppinga, Hans C.J. de Boer, Marieke J. van Son, Jochem R.N. van der Voort van Zyp, T. Willigenburg, Max Peters, Jan J W Lagendijk, Marinus A. Moerland
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 30, Iss, Pp 7-14 (2021)
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology
Highlights • Biochemical failure rates after focal salvage high-dose-rate brachytherapy are high. • Evidence on predictors for failure is limited to whole-gland salvage radiotherapy. • Two prediction models for biochemical failure were develope
Autor:
Jochem R.N. van der Voort van Zyp, Marinus A. Moerland, Sandrine M.G. van de Pol, Marieke van Son, Wietse S.C. Eppinga, Max Peters, Jan J W Lagendijk
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 27, Iss, Pp 1-7 (2021)
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology
Highlights • Severe toxicity is as low as 3% (GU), 0% (GI) and 15% (ED). • Lower impact is predicted for patients with favorable function at baseline. • Lower dose to the urethra (D10%
Background and purpose Local re-treatment of radiorecu
Background and purpose Local re-treatment of radiorecu
Autor:
Marnix J.A. Rasing, Max Peters, Marieke van Son, Marinus A. Moerland, Wietse Eppinga, Sandrine M.G. van de Pol, Juus Noteboom, Jan Lagendijk, Jochem R.N. van der Voort van Zyp
Publikováno v:
Radiotherapy and Oncology. 180:109495
Autor:
J.R.N. Van der Voort van Zyp, Wietse S.C. Eppinga, T. Willigenburg, J.J.W. Lagendijk, H. de Boer, Marinus A. Moerland, Max Peters, S. van de Pol, M. van Son
Publikováno v:
Radiotherapy and Oncology. 158:S25-S27
Autor:
Marinus A. Moerland, Jan J W Lagendijk, Jochem R.N. van der Voort van Zyp, Hans C.J. de Boer, T. Willigenburg, J. Hes, E. Beld
Publikováno v:
Physics and Imaging in Radiation Oncology, Vol 15, Iss, Pp 60-65 (2020)
Physics and Imaging in Radiation Oncology
Physics and Imaging in Radiation Oncology
Highlights • SBRT may provide a non-invasive treatment option for recurrent prostate cancer. • MR-Linac single fraction 19 Gy treatment of recurrent prostate cancer is feasible. • MR-Linac dose distributions for the target were comparable to HD